Front. Oncol.Frontiers in OncologyFront. Oncol.2234-943XFrontiers Media S.A.10.3389/fonc.2025.1646064OncologyCorrectionCorrection: Knowledge mapping of global trends in DNA damage repair-related breast cancer research: a bibliometric studyHuangYajing1*WeiShumei1HuKaimin2XiangXueping11Department of Pathology, the Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China2Department of Breast Surgery and Oncology, the Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China
Edited and reviewed by: Giuseppe Giaccone, Cornell University, United States
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A Correction on Knowledge mapping of global trends in DNA damage repair-related breast cancer research: a bibliometric study By Huang Y, Wei S, Hu K and Xiang X (2025) Front. Oncol. 15:1562539. doi: 10.3389/fonc.2025.1562539DNA damage repairbreast cancerglobal trendsbibliometric studyCiteSpaceVOSviewersection-in-acceptanceBreast Cancer
There was a mistake in Figure 9D as published. In the published form of Figure 9D, two drugs somehow were not presented, including Stenoparib (distributed in one clinical trial) and Tuvusertib (distributed in one clinical trial). The corrected presentation of Figure 9D appears below.
(A) Annual distribution of a number of clinical trials. (B) Distribution of phases in clinical trials. (C) Distribution of therapy types in clinical trials. (D) Distribution of DDR-related drugs in clinical trials.
Image contains four bar charts depicting clinical trial distributions. Chart A shows the number of trials per year from 2008 to 2024, peaking in 2024 with 11. Chart B highlights trial phases, with phase II having the most at 20. Chart C details therapy types, dominated by maintenance and palliative treatment with 36 trials. Chart D shows DDR-related drug distribution, with Olaparib being the most used at 16.
The original version of this article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.